drugset / Trial / NCT07563010
Menin-Inhibitor Targeted Maintenance in AML
Phase 2
Not yet recruiting
146 enrolled
Center for International Blood and Marrow Transplant Research
Dana-Farber Cancer Institute · collabNational Marrow Donor Program · collab
RandomizedParallel-groupTriple-blindSupportive care
Summary
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML. In addition to suppressing leukemogenic transcriptional programs and promoting leukemic differentiation, menin inhibition has been shown to modulate epigenetic states linked to antigen presentation and immune recognition. These properties provide a strong biological rationale for evaluating revumenib as maintenance therapy following alloHCT, with the goal of suppressing residual leukemic clones while preserving or enhancing GVL activity during immune reconstitution.
Timeline
- Start
- 2026-12
- Primary completion
- 2031-06
- Completion
- 2031-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Revumenib | Small molecule | — | Oral |